A list of the most resent publications where the Genomics Core Facility has contributed with services is presented (partial list, due to the difficulty of identifying publications using results generated by our services)

Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA. Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report. BMC Cancer. 2017 Jan 6;17(1):29. doi: 10.1186/s12885-016-2992-8.

Chymkowitch P, Nguéa P A, Aanes H, Robertson J, Klungland A, Enserink JM. TORC1-dependent sumoylation of Rpc82 promotes RNA polymerase III assembly and activity. Proc Natl Acad Sci U S A. 2017 Jan 17. pii: 201615093. doi: 10.1073/pnas.1615093114. [Epub ahead of print]

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad K-AM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Kjersti Flatmark and Lyng H. Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. British Journal of Cancer 6 September 2016; doi: 10.1038/bjc.2016.278

Behnan J, Stangeland B, Langella T, Finocchiaro G, Murrell W, Brinchmann JE. Ultrasonic Surgical Aspirate is a Reliable Source For Culturing Glioblastoma Stem Cells. Sci Rep. 2016 Sep 8;6:32788. doi: 10.1038/srep32788.

Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA. Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene. PLoS One. 2016 Sep 29;11(9):e0163859. doi: 10.1371/journal.pone.0163859.

Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å. TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients. Front Genet. 2016 May 11;7:85. doi: 10.3389/fgene.2016.00085.

Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan A, Myklebost O, Meza-Zepeda LA. Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. Oncotarget. 2016 Feb 2;7(5):5273-88. doi: 10.18632/oncotarget.6567.

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4.

Oldenburg AR, Collas P. Mapping Nuclear Lamin-Genome Interactions by Chromatin Immunoprecipitation of Nuclear Lamins. Methods Mol Biol. 2016;1411:315-24. doi: 10.1007/978-1-4939-3530-7_20.

Hoff AM, Alagaratnam S, Zhao S, Bruun J, Andrews PW, Lothe RA, Skotheim RI. Identification of Novel Fusion Genes in Testicular Germ Cell Tumors. Cancer Res. 2016 Jan 1;76(1):108-16. doi: 10.1158/0008-5472.CAN-15-1790.

Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ. Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel. Oncotarget. 2016 Mar 15;7(11):12267-85. doi: 10.18632/oncotarget.7860.

Andreassen R, Rangnes F, Sivertsen M, Chiang M, Tran M, Worren MM. Discovery of miRNAs and Their Corresponding miRNA Genes in Atlantic Cod (Gadus morhua): Use of Stable miRNAs as Reference Genes Reveals Subgroups of miRNAs That Are Highly Expressed in Particular Organs. PLoS One. 2016 Apr 29;11(4):e0153324. doi: 10.1371/journal.pone.0153324.

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH. Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy. Cancer Res Treat. 2016 Jul 28. doi: 10.4143/crt.2016.080. [Epub ahead of print]

Hasvold G, Lund-Andersen C, Lando M, Patzke S, Hauge S, Suo Z, Lyng H, Syljuåsen RG. Hypoxia-induced alterations of G2 checkpoint regulators. Mol Oncol. 2016 May;10(5):764-73. doi: 10.1016/j.molonc.2015.12.015. Epub 2016 Jan 8.

Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A1, Kuehl WM, Holien T. VOLIN and KJON-Two novel hyperdiploid myeloma cell lines. Genes Chromosomes Cancer. 2016 Jun 16. doi: 10.1002/gcc.22388. [Epub ahead of print]

Gervin K, Page CM, Aass HC, Jansen MA, Fjeldstad HE, Andreassen BK, Duijts L, van Meurs JB, van Zelm MC, Jaddoe VW, Nordeng H, Knudsen GP, Magnus P, Nystad W, Staff AC, Felix JF, Lyle R. Cell type specific DNA methylation in cord blood: a 450K-reference data set and cell count-based validation of estimated cell type composition. Epigenetics. 2016 Aug 5:0. [Epub ahead of print].

Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O. Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma. Oncotarget. 2016 Jul 9. doi: 10.18632/oncotarget.10518. [Epub ahead of print].

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S4, Flatmark K, Redalen KR, Ree AH. Systemic release of osteoprotegerin during oxaliplatincontaining induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. Oncotarget. 2016 Apr 26. doi: 10.18632/oncotarget.8995. [Epub ahead of print].

Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7(15):19997-20015. doi: 10.18632/oncotarget.7671.

Vandsemb EN, Bertilsson H, Abdollahi P, Størkersen Ø, Våtsveen TK, Rye MB, Rø TB, Børset M, Slørdahl TS. Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration. J Transl Med. 2016 Mar 15;14:71. doi: 10.1186/s12967-016-0830-z.

Kierulf-Vieira KS, Sandberg CJ, Grieg Z, Günther CC, Langmoen IA, Vik-Mo EO. Wnt inhibition is dysregulated in gliomas and its re-establishment inhibits proliferation and tumor sphere formation. Exp Cell Res. 2016 Jan 1;340(1):53-61. doi: 10.1016/j.yexcr.2015.12.010. Epub 2015 Dec 19.

Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Øyjord T, Risa Ø, Nygaard V, Mælandsmo GM, Prasmickaite L. Metabolic reprogramming supports the invasive phenotype in malignant melanoma. Cancer Lett. 2015 Sep 28;366(1):71-83. doi: 10.1016/j.canlet.2015.06.006. Epub 2015 Jun 18.

Joel M, Mughal AA, Grieg Z, Murrell W, Palmero S, Mikkelsen B, Fjerdingstad HB, Sandberg CJ, Behnan J, Glover JC, Langmoen IA, Stangeland B. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo. Mol Cancer. 2015 Jun 17;14:121. doi: 10.1186/s12943-015-0398-x.

Ollikainen M, Ismail K, Gervin K, Kyllönen A, Hakkarainen A, Lundbom J, Järvinen EA, Harris JR, Lundbom N, Rissanen A, Lyle R, Pietiläinen KH, Kaprio J. Genome-wide blood DNA methylation alterations at regulatory elements and heterochromatic regions in monozygotic twins discordant for obesity and liver fat. Clin Epigenetics. 2015 Apr 2;7:39. doi: 10.1186/s13148-015-0073-5. eCollection 2015.

Reppe S, Noer A, Grimholt RM, Halldórsson BV, Medina-Gomez C, Gautvik VT, Olstad OK, Berg JP, Datta H, Estrada K, Hofman A, Uitterlinden AG, Rivadeneira F, Lyle R, Collas P, Gautvik KM. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women. J Bone Miner Res. 2015 Feb;30(2):249-56. doi: 10.1002/jbmr.2342.

Lando M, Fjeldbo CS, Wilting SM, Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer. Epigenetics, (2015) (in press).

Chymkowitch P, Nguéa A, Aanes H,  Koehler CJ, Thiede T, Lorenz S, Meza-Zepeda LA, Arne Klungland A and Enserink JM.  Sumoylation of Rap1 Mediates the Recruitment of TFIID to Promote Transcription of Ribosomal Protein Genes. Genome Research. (2015) Mar 23. [Epub ahead of print].

Lund EG, Duband-Goulet I, Oldenburg A, Buendia B, Collas P. Distinct features of lamin A-interacting chromatin domains mapped by ChIP-sequencing from sonicated or micrococcal nuclease-digested chromatin. Nucleus. 2015;6(1):30-9.


Joel M, Mughal AA, Grieg Z, Murrell W, Palmero S, Mikkelsen B, Fjerdingstad HB, Sandberg CJ, Behnan J, Glover JC, Langmoen I, Stangeland B. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumorgrowth in vivo. Mol Cancer. 2015 Jun 17;14(1):121.


Ragnum HB, Vlatkovic L, Lie AK, Axcrona A, Julin CH, Frikstad KM, Hole KH, Seierstad T and Lyng H. The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer. Br J Cancer. 2015 Jan 20;112(2):382-90.

Ollikainen M, Ismail K, Gervin K, Kyllönen A, Hakkarainen A, Lundbom J, Järvinen EA, Harris JR, Lundbom N, Rissanen A, Lyle R, Pietiläinen KH, Kaprio J. Genome-wide blood DNA methylation alterations at regulatory elements and heterochromatic regions in monozygotic twins discordant for obesity and liver fat. Clin Epigenetics. 2015 Apr 2;7(1):39.

 
 
Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodak D, Meza-Zepeda LA, Sandvik A, Wader KF, Misund K, Sundan A, Aarset H and Waage A. Clinical and biological implications of BRAF V600E mutation in multiple myeloma. Blood Cancer Journal. (2015) Mar 20;5:e299.

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O and Munthe E. Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA. Oncotarget. (2015) Feb 10;6(4):2451-65.

Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Martin Peifer M, Plenker D, Heuckman JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z, Solomon B, Petersen I, Clement JH, Sänger J, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Buettner R, Wolf J, Brambilla E, Vingron M, Perner S, Haas SA and Thomas RK. Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology. (2015)Jan 5;16(1):7.

Garsed DW, Marshall OJ, Corbin VDA, Hsu A, Popkiss S, Li J, Feng Z-P, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O,Meza-Zepeda LA, Holloway AJ, Copin A, Pedeutour F, Choo KHAC, D’Amore M,  Anthony T. Papenfuss AT and Thomas DM. The Architecture and Evolution of a Cancer Neochromosome. Cancer Cell. (2014) Nov 10;26(5):653-67.

Chilamakuri CSR, Lorenz S, Madoui M-A, Vodák D, Sun J, Hovig E, Myklebost O and Meza-Zepeda LA. Performance comparison of four exome capture systems for deep sequencing. BMC Genomics. (2014) Jun 9;15:449  HIGHLY ACCESSED.

Johansen I and Andreassen R. Validation of miRNA genes suitable as reference genes in qPCR analyses of miRNA gene expression in Atlantic salmon (Salmo salar). BMC Research Notes 2014, 7:945.
Håkelien A-M, Bryne, JC, Harstad KG, Lorenz S, Paulsen J, Sun J, Mikkelsen TS, Myklebost O and Meza-Zepeda LA. The regulatory landscape of osteogenic differentiation. Stem Cells. (2014) Oct;32(10):2780-93.

Skårn M, Noordhuis P, Wang MY, Veuger MJT, SH Kresse SH, Egeland EV, Micci F, Namløs HM, Håkelien AM, Olafsrud SM, Lorenz S, Haraldsen G, Kvalheim G, Meza-Zepeda LA and Myklebost O. Generation and Characterization of an Immortalized Human Mesenchymal Stromal Cell Line. Stem Cells and Development. (2014) Oct 1;23(19):2377-89.

Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O and Meza-Zepeda LA. Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model. Molecular Cancer. (2014) Apr 28;13:93.

Nome T, Thomassen GOS, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rongnum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA and Skotheim RI. Common fusion transcripts identified in colorectal cancer cell lines by high throughput RNA sequencing. Translational Oncology(2013) Oct 1;6(5):546-53. eCollection.

Ragnum HB1, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):753-60.

Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM,Meza-Zepeda LAand Myklebost O. Functional characterization of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. British Journal of Cancer. (2013) Oct 15;109(8):2228-36.

Schee K, Lorenz S, Molton Worren M, Günther C-C, Holden M, Hovig E, Fodstad Ø, Meza-Zepeda LA, Flatmark K. Deep sequencing the microRNA transcriptome in colorectal cancer. PLoS One. (2013) Jun 18;8(6):e66165.

Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC and Cleton-Jansen AM. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer.  (2013) 20;13(1):245.

Qu S, Olafsrud SM, Meza-Zepeda LA, Saatcioglu F. Rapid Gene Expression Changes in Peripheral Blood Lymphocytes upon Practice of a Comprehensive Yoga Program. PLoS One. (2013) 8(4):e61910.

Herlofsen SR, Bryne JC, Høiby T, Wang L, Issner R, Zhang X, Coyne MJ, Boyle P, Gu H, Meza-Zepeda LA, Collas P, Mikkelsen TS, Brinchmann JE. Genome-wide map of quantified epigenetic changes during in vitro chondrogenic differentiation of primary human mesenchymal stem cells. BMC Genomics. (2013) 14(1):105.

Andreassen R, Worren MM and Høyheim B. Discovery and characterization of miRNA genes in atlantic salmon (Salmosalar) by use of a deep sequencing approach. BMC Genomics. 2013 Jul 17;14:482.
Ohnstad HO, CastroR, Sun J, Heintz K-M,Vassilev LT, BjerkehagenB, Kresse SH, Meza-Zepeda LA and Myklebost O. TP53 and MDM2 status can determine response to therapies in sarcomas. Cancer. (2013) 119(5):1013-22. BMCGenomics2013,14:482.

Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfør K, Holm R, Kristensen GB, Steenbergen RD, Lyng H. Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling. J Pathol. (2013). [Epub ahead of print].

Bjørnstad L, Meza TJ, Otterlei M, Olafsrud SM, Meza-Zepeda LA and Falnes P. The human AlkB homologue 4 interacts with proteins associated with transcription. PLoS One. (2012) 7(11):e49045.

Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IHG, Stine H Kresse SH, Kuijjer ML, Serra M, Cleton-JansenA-M and Myklebost O. Modulation of the Osteosarcoma Expression Phenotype by MicroRNAs. PLoS One. (2012) 7(10):e48086.

Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen A-M, Serra M, Liestøl K, Hogendoorn PCW, Hovig E, Myklebost O and Meza-Zepeda LA. Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS One. (2012)7(11):e48262

Ohnstad HO, CastroR, Sun J, Heintz K-M,Vassilev LT, BjerkehagenB, Kresse SH, Meza-Zepeda LA and Myklebost O. TP53 and MDM2 status can determine response to therapies in sarcomas. Cancer. (2013) 119(5):1013-22.

Reikvam DH, Derrien M, Islam R, Erofeev A, Grcic V, Sandvik A, Gaustad P, Meza-Zepeda LA, Jahnsen FL, Smidt H, Johansen FE. Epithelial-microbial cross-talk in polymeric Ig receptor deficient mice. European Journal of Immunology (2012) Nov;42(11):2959-70.

Chymkowitch P, Eldholm V, Lorenz S, Zimmermann C, Lindvall JM, Bjørås M, Meza-Zepeda LA and Enserink JM. Cdc28 Kinase activity regulates the basal transcription machinery at a subset of genes. Proceedings of the National Academy of Sciences. (2012) 109(26):10450-5.

Kuijjer ML, Rydbeck H, Kresse SH, Buddingh EP, Lid AB, Roelofs H, Bürger H, Myklebost O, Hogendoorn PC, Meza-Zepeda LA, Cleton-Jansen AM. Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes and Cancer. (2012) Jul;51(7):696-706.

Skårn M, Namløs HM, Noordhuis P, Wang MY, Meza-Zepeda LA, Myklebost O. Adipocyte Differentiation of Human Bone Marrow-Derived Stromal Cells is Modulated by microRNA-155, microRNA-221 and microRNA-222. Stem Cells Development. (2012) Apr 10;21(6):873-83.
Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A and Myklebost O. Preclinical Xenograft models of human sarcoma show nonrandom loss of aberrations. Cancer, (2012). 118(2):558-70.

Kalanxhi E and Dahle J. Transcriptional responses in irradiated and bystander fibroblasts after low dose α-particle radiation. International Journal of Radiation Biology, (2012) Oct;88(10):713-719.

Kalanxhi E and Dahle J. Genome-Wide Microarray Analysis of Human Fibroblasts in Response to γ Radiation and the Radiation-Induced Bystander Effect. Radiation Research, (2012), 177(1):35-43.

Halle C, Andersen E, Lando M,  Aarnes E-K, Hasvold G, Holden M, Syljuåsen RG, Sundfør K, B. Kristensen GB, Holm R, Malinen E and Lyng H. Hypoxia-Induced Gene Expression in Chemoradioresistant Cervical Cancer Revealed by Dynamic Contrast-Enhanced MRI. Cancer Research, (2012) 72; 5285.

Gervin K, Vigeland MD, Mattingsdal M, Hammerø M, Nygård H, Olsen AO, Brandt I, Harris JR, Undlien DU and Lyle R. DNA Methylation and Gene Expression Changes in Monozygotic Twins Discordant for Psoriasis: Identification of Epigenetically Dysregulated Genes. PLoS Genet. (2012) 8(1): e1002454.

Dahlback H-S, Brandal P, Krossnes BK, Fric R, Meling TR, Meza-Zepeda LA, Danielsen HE and Heim S. Multiple chromosomal monosomies are characteristic of giant cell ependymoma. Human Pathology, (2011) Dec;42(12):2042-6.

Kuijjer ML, Namløs HM, Hauben EI, Machado I, Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PCW, Meza-Zepeda LA, Myklebost O and Cleton-Jansen AM. mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Medical Genomic. (2011) 20;4:66.

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma. BMC Cancer. (2011) Oct 20;11(1):455.

Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør L, Kristensen GB, Holm R, and Lyng H. Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node–Negative Cervical Cancer. Clinical Cancer Research (2011) 17; 5501.

Halle C, Lando M, Sundfør K, Kristensen GB, Holm R, Lyng H. Phosphorylation of EGFR measured with in situ proximity ligation assay: Relationship to EGFR protein level and gene dosage in cervical cancer. Radiotherapy and Oncology (2011) 101 (1): 152–157.

Herlofsen SR, Küchler AX, Melvik JE and Brinchmann JE. Chondrogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells in Self-Gelling Alginate Discs Reveals Novel Chondrogenic Signature Gene Clusters. Tissue Engineering  Part A. (2011)  17(7-8): 1003–1013.

 

 
 
 
 
 
 


News

Feb 24, 2016

The HiSeq 4000 build upon the existing HiSeq 2500 platform using the new HiSeq X patterned flow cell technology, providing unparalleled speed and performance. The dual-flow cell HiSeq 4000 System delivers the highest throughput and lowest price per sample across multiple applications. The new sequencer will provide users will faster turnaround time (run time is 3 days compared to 6-11 days in HiSeq 2500) and higher quality, more data per run and longer reads (150 bp paired-end).

Feb 15, 2016

The Oslo University Hospital Genomics and Bioinformatics Core Facilities will relocate to the new Oslo Cancer Cluster Innovation park to colocalise with the section for Molecular Pathology. The colocalisation will facilitate the technology and competence transfer from our genomics environment to accelerate the implementation of high-throughput sequencing for clinical stratification of cancer patients.


Contact Information:

oslo<at>genomics.no 

Visiting address:
Genomics Core Facility (Room 3-F8-04)
Department of Core facilities
Institute for Cancer Research
New OCCI-building 
 
Norwegian Radium Hospital 
Ullernchaussen 66, Lamell 3, 2B 
NO-0379 Oslo, NORWAY

+47 - 9183 2772 Laboratory
+47 - 9183 3425 Office

Head of Core Facility
Leonardo A. Meza-Zepeda, Dr. philos.

................................................................

................................................................